By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
CoinworldstoryCoinworldstoryCoinworldstory
  • HOME
  • CRYPTO
    • AI
    • BOTS
    • ICO
    • AIRDROP
      • Featured Airdrops
    • Price Prediction
    • EXCHANGE
      • Best Centralized Exchange List 2025
      • Best Decentralized Exchange List 2025
    • ALTCOIN
    • Alt Coin Signal
    • Crypto Analysis
    • Bitcoin Loan
    • Bitcoin Mining
    • WALLETPRO
  • PR
    PR
    If You Looking For Submit Cryptocurrency Press Releases Than Coinworldstory Is Best Choice For Crypto Press Release Submission
    Show More
    Top News
    The Aerum Ecosystem, A Market-Oriented Hub
    The Aerum Ecosystem, A Market-Oriented Hub
    3 years ago
    Worldwide Blockchain and AI communities team up to produce over 100 potential solutions to aide coronavirus pandemic
    Worldwide Blockchain And Ai Communities Team Up To Produce Over 100 Potential Solutions To Aide Coronavirus Pandemic
    4 years ago
    Gravity Sport, a leading-edge NFT marketplace, becomes a second partner of Parma Calcio 1913
    2 years ago
    Latest News
    BitMine Immersion (BMNR) Announces ETH Holdings Exceeding 2.83 Million Tokens and Total Crypto and Cash Holdings of $13.4 Billion
    8 hours ago
    Bepay money to Launch $1 Million Bitcoin Rewards Program at Invest Web3 Forum Dubai 2025
    9 hours ago
    BC.GAME News Backs Deccan Gladiators as Title Sponsor in 2025 Abu Dhabi T10 League
    11 hours ago
    Cango Inc. Announces September 2025 Bitcoin Production and Mining Operations Update
    15 hours ago
  • NEWS
    • Mining
    • Altcoins
    • Ban
    • BANKING/FINANCE NEWS
    • Bitcoin
    • Blockchain
    • CRYPTO CRIME
    • Ethereum
    • Exchange News
    • Government News
    NEWSShow More
    Ten Largest Property Firms by Market Cap In 2025
    Ten Largest Property Firms by Market Cap In 2025
    19 hours ago
    Why Shiba Inu Large Transaction Volume Is Dropping Fast
    Why Shiba Inu Large Transaction Volume Is Dropping Fast
    4 weeks ago
    Crypto Tax Rules In Russia – What You Should Know
    Crypto Tax Rules In Russia – What You Should Know
    1 month ago
    Elon Musk Considering Blockchain To Bolster us Government Efficiency
    Elon Musk Considering Blockchain To Bolster us Government Efficiency
    1 month ago
    10 Next Big Meme Coin To Explode
    10 Next Big Meme Coin To Explode
    1 month ago
  • MORE
    • Guide
    • Only Best
    • Off Topic
    • Best Affiliate Marketing
    • Best Affiliate Programs
    • BOTS
    • Trusted Currency Exchanger Platform
    • Blockchain Games
    • Metaverse Review : Best Metaverse Program Review
    • Online Survey
    • Payment Platform
  • VPN
  • Contact Us
Reading: 10 Best Biotech Stocks To Buy | Top Growth Opportunities
Share
Notification Show More
Font ResizerAa
CoinworldstoryCoinworldstory
Font ResizerAa
  • ADVERTISEMENT
  • SUBMIT PR
  • CONTACT
  • GUEST POST
  • ABOUT US
  • DMCA
  • SITEMAP
  • DISCLAIMER
  • PRIVACY POLICY
Search
  • HOME
  • CRYPTO
    • AI
    • BOTS
    • ICO
    • AIRDROP
    • Price Prediction
    • EXCHANGE
    • ALTCOIN
    • Alt Coin Signal
    • Crypto Analysis
    • Bitcoin Loan
    • Bitcoin Mining
    • WALLETPRO
  • PR
  • NEWS
    • Mining
    • Altcoins
    • Ban
    • BANKING/FINANCE NEWS
    • Bitcoin
    • Blockchain
    • CRYPTO CRIME
    • Ethereum
    • Exchange News
    • Government News
  • MORE
    • Guide
    • Only Best
    • Off Topic
    • Best Affiliate Marketing
    • Best Affiliate Programs
    • BOTS
    • Trusted Currency Exchanger Platform
    • Blockchain Games
    • Metaverse Review : Best Metaverse Program Review
    • Online Survey
    • Payment Platform
  • VPN
  • Contact Us
Have an existing account? Sign In
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Home » Blog » 10 Best Biotech Stocks To Buy | Top Growth Opportunities
Banking & Finance

10 Best Biotech Stocks To Buy | Top Growth Opportunities

Frisco d'Anconia
Last updated: 01/10/2025 5:28 PM
Frisco d'Anconia
5 months ago
Share
Disclosure: We are not a registered broker-dealer or an investment advisor. The services and information we offer are for sophisticated investors, and do not constitute personal investment advice, which of necessity must be tailored to your particular means and needs. !
10 Best Biotech Stocks To Buy | Top Growth Opportunities
SHARE

In this article, I will highlight companies with successful innovation, promising pipelines, and solid financials while discussing the best biotech stocks to buy.

Contents
  • Key Points & Best Biotech Stocks To Buy List
  • 10 Best Biotech Stocks To Buy
    • 1.Vertex Pharmaceuticals Incorporated
    • 2.Moderna, Inc.
    • 3.BioNTech SE
    • 4.Exelixis, Inc
    • 5.Regeneron Pharmaceuticals, Inc
    • 6.Summit Therapeutics, Inc
    • 7.Axsome Therapeutics, Inc
    • 8.Halozyme Therapeutics, Inc
    • 9.BioMarin Pharmaceuticals Inc
    • 10.Ascentage Pharma
  • Conclusion

These stocks are poised to lead in growth in 2025, so if you’re keen on market leaders or fresh market entrants, these stocks will not disappoint. Keep reading to learn about vital picks that stand to radically advance healthcare and yield remarkable investment profits.

Key Points & Best Biotech Stocks To Buy List

Company NameKey Point
Vertex Pharmaceuticals IncorporatedKnown for its breakthrough treatments for cystic fibrosis.
Moderna, Inc.Pioneered mRNA vaccine technology; key player in COVID-19 vaccine rollout.
BioNTech SEGerman biotech best known for its mRNA COVID-19 vaccine developed with Pfizer.
Exelixis, Inc.Focuses on oncology, especially kidney and liver cancer treatments.
Regeneron Pharmaceuticals, Inc.Developed EYLEA for eye diseases and monoclonal antibodies for COVID-19.
Summit Therapeutics, Inc.Focused on antibiotic innovation and targeted oncology therapies.
Axsome Therapeutics, Inc.Specializes in CNS disorders, with key drugs for depression and migraines.
Halozyme Therapeutics, Inc.Known for its ENHANZE® drug delivery platform enhancing biologic therapies.
BioMarin Pharmaceuticals Inc.Develops therapies for rare genetic diseases, including enzyme replacement.
Ascentage PharmaChinese biotech focused on apoptosis-targeted cancer and hepatitis B drugs.

10 Best Biotech Stocks To Buy

1.Vertex Pharmaceuticals Incorporated

Industry experts consider Vertex Pharmaceuticals (NASDAQ: VRTX) to be one of the most industries-ready biotech stock to invest in 2025 due to its impressive financial data and progressive pipeline.

The firm continues to lead in the cystic fibrosis (CF) market, with remedies like Trikafta bringing in more than $10 billion yearly. Vertex’s diversification efforts are apparent with the most recent FDA approvals for Casgevy, a gene-editing therapy for sickle cell disease, and Journavx, a non-opioid pain medication.

- Advertisement -
Vertex Pharmaceuticals Incorporated

With a balanced sheet of $11.2 billion in cash and low debt, Vertex is positioned for growth. Analysts predict 2025 revenues to be between 11.75 – 12 billion suggesting an increased market presence for the firm.

FeatureDescription
Focus AreasCystic fibrosis treatments, rare diseases
Key DrugsTrikafta, Kalydeco
Market PositionLeader in cystic fibrosis therapies
PipelineExpanding into pain management and gene editing
Financial HealthStrong revenue growth with steady R&D investment
Visit Now

2.Moderna, Inc.

Investors have encountered hurdles as Moderna Inc. (NASDAQ:MRNA) remains a compelling biotech stock in the long-run in 2025.

The firm assumes that through a set target of 2025, revenues would lie within an estimate of 1.5 billion and 2.5 billion which is lower than 3.2 billion for 2024; this is primarily due to dwindling COVID-19 vaccination sales. To counter these issues, Moderna plans to cut costs by $1 billion in 2025 with an additional cut of $500 million in 2026.

Included in Moderna’s strong pipeline are late stage candidates for RSV, cytomegalovirus, and personalized cancer vaccines created in partnership with Merck.

The company expects as much as 10 product approvals by 2027, these could add revenues to help diversify the firm’s matrix. With a sustainable position of cash equals 9.5 billion by the bank at the end of 2024, Moderna is slated towards funding their R&D initiatives.

- Advertisement -
Moderna, Inc.

Short term profits for now seem to be a problem, however, analysts expect the firm to return to profitability by the year 2029.

With the application of their innovative mRNA platform and consideration on focusing strategic targets approach areas of high value proposition, there are significant opportunities for long term growth potential for investors willing to manage the short term bumps.

FeatureDescription
Technology PlatformmRNA technology platform
Key ProductsCOVID-19 vaccines, RSV vaccine candidates
PipelinePersonalized cancer vaccines, infectious disease vaccines
Financial PositionRobust cash reserves with ongoing cost reductions
Growth PotentialDiversifying revenue beyond COVID-19 vaccines
Visit Now

3.BioNTech SE

BioNTech’s (NASDAQ: BNTX) stock seems like a strong buy heading into 2025 due to its solid oncology pipeline and strong financials.

- Advertisement -

The company is currently working on a BANT327/PM8002, a bispecific antibody against PD-L1 and VEGF-A; it is in Phase 2/3 trials for non-small cell lung cancer and breast cancer (triple negative).

BioNTech SE

Besides, BioNTech, in partnership with Genentech, is working on an individualized mRNA cancer vaccine, autogene cevumeran.

Though revenue is anticipated to decline to €1.7 – 2.2 billion in 2025, analysts continue to have a ‘Strong Buy’ consensus, with a 12-month price target estimated at $146.17 which presents potential upside.

FeatureDescription
SpecializationmRNA-based immunotherapies and oncology
Key ProductsCOVID-19 vaccines, cancer vaccine candidates
PipelineBispecific antibodies, personalized cancer vaccines
Strategic PartnershipsCollaboration with Genentech, Pfizer
Market OutlookStrong growth expected despite short-term revenue dips
Visit Now

4.Exelixis, Inc

Exelixis Inc. (NASDAQ: EXEL) is one of the distinguished biotechs to look out for in 2025 owing to its solid financials and an alluring oncology pipeline.

Its flagship drug, Cabometyx, still yields enormous revenue and is expected to bring in total revenue of somewhere between $2.15-2.25 billion for the year 2025.

Exelixis, Inc

Zanzalintinib, Exelixis’ other asset, is also zanzalintinib being tested in several pivotal trials with important data readouts anticipated in the second half of 2025.

With regards to stock evaluation, analysts have a “buy” rating with the 12 months price target averaging at $37.59, showcasing some belief in company growth.

FeatureDescription
Therapeutic FocusOncology
Key DrugsCabometyx
PipelineZanzalintinib, other targeted therapies
Revenue ForecastProjected steady revenue growth
Analyst RatingsGenerally positive “Buy” consensus
Visit Now

5.Regeneron Pharmaceuticals, Inc

Biotech is one of the sectors that is expected to yield good returns in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) seems to be one of them as it has strong financials and a promising pipeline.

In , the company’s revenue increased by 8% year on year, reaching $14.2 billion and announcing its first quarterly dividend.

Regeneron Pharmaceuticals, Inc

This reflects sustained growth and confidence in the business. Ascendings sales are driven by key products such as Dupixent and EYLEA and linvoseltamab for multiple myeloma and odronextamab for lymphoma add to the company’s growing oncology portfolio.

There is a consensus “Buy” recommendation from analysts with a 12-month price estimate of 907.39 USD, translating to strong potential upside.

FeatureDescription
Therapeutic AreasImmunology, oncology, ophthalmology
Key ProductsDupixent, EYLEA
PipelineNew oncology therapies like linvoseltamab, odronextamab
Financial StrengthStrong revenue growth and dividend initiation
Analyst OutlookPositive with significant upside potential

6.Summit Therapeutics, Inc

Summit Therapeutics Inc. SMMT has been identified as a stock to watch for 2025 due to the oncology pipeline and strong market performance.

The company’s lead candidate, ivonescimab, achieved a clinical milestone by demonstrating 49% lower risk of progression in disease compared to Merck’s Keytruda in a late-stage non-small cell lung cancer trial.

This has led to a positive response from analysts with Goldman Sachs raising its price target to $41 and HC Wainwright maintaining a $44 target, signaling strong upside potential.

Summit Therapeutics, Inc

Although the company continues to face financial headwinds including an annual cash burn of $157 million, Summit’s cash reserves of $412 million offer 2.6 years of runway which supports investment in the company’s promising pipeline.

Summit’s strategic focus on groundbreaking therapies combined with a market cap of $17.79 billion and a share price of $25.77 as of May 23, 2025 makes it an attractive candidate in the biotech sector.

FeatureDescription
FocusOncology, precision medicine
Lead CandidateIvonescimab (NSCLC)
Clinical Results49% reduction in disease progression risk
FinancialsCash runway of 2.6 years with ongoing investment
Analyst RatingsPositive price target increases

7.Axsome Therapeutics, Inc

Axsome Therapeutics Inc. (NASDAQ: AXSM) will emerge as a promising investment opportunity for mid 2025 due to advancements in the Central Nervous System (CNS) therapeutics. For 1Q 2025, the net product revenue was reported to be $121.5 million with an increase of 62% year over year which enabled AUVELITY® to reach 96.2 million dollars in sales with 80% increase.

Under the late stage pipeline, Axsome has AXS-05 for managing agitation in Alzheimer’s patients, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia, with plans for regulatory submission in the year 2025. SYMBRAVO® was also approved by FDA for acute migraine treatment with plans for commercial launch in June 2025.

Axsome Therapeutics, Inc

Analysts set the consensus as Strong Buy with a target of $172.14 for 12 months showing upside of roughly 64% from price of $104.35 currently. With such an impressive product portfolio and ample capital, Axsome will excel throughout the remainder of the biotech growth phase.

FeatureDescription
FocusCentral nervous system (CNS) disorders
Key ProductsAUVELITY®, SYMBRAVO®
PipelineAXS-05 (Alzheimer’s agitation), AXS-12 (narcolepsy), AXS-14 (fibromyalgia)
Recent Performance62% revenue growth year-over-year
Market PotentialStrong analyst “Strong Buy” consensus

8.Halozyme Therapeutics, Inc

In 2025, Halozyme Therapeutics Inc. (NASDAQ: HALO) is forecasted to remain one of the most lucrative biotech stocks because of its proprietary ENHANZE® drug delivery system and robust financial results.

The company reported revenue of $264.86 million for Q1 2025, a 35% increase year-over-year, and an adjusted EPS of $1.11 which is a 41% rise. Contributions to growth came from key products such as VYVGART Hytrulo, Phesgo, and Darzalex SC.

Halozyme Therapeutics, Inc

Analysts still hold a positive view despite concern from potential CMS draft guidance relating to combination products and regulatory headwinds. The analyst consensus price target is $63.56 which is a considerable upside from the current share price of $53.75.

FeatureDescription
Core TechnologyENHANZE® drug delivery platform
Key ProductsDarzalex SC, Phesgo, VYVGART Hytrulo
Financial Performance35% revenue growth in Q1 2025
Regulatory RisksPotential challenges from CMS draft guidance
Analyst ConsensusPositive outlook with price target upside

9.BioMarin Pharmaceuticals Inc

BioMarin Pharmaceuticals Inc. (NASDAQ: BMRN) is one of the leading biotech companies focusing on the development of therapies for rare genetic disorders. During Q1 2025, BIOMARIN reported total revenues of $745 million, which was an increase of 15% from the previous year.

This was driven by exceptional sales of VOXZOGO®, which grew 40% in revenue to $214 million. The company maintained its full-year 2025 revenue guidance of $3.1–$3.2 billion and EPS guidance of $4.20-4.40.

BioMarin Pharmaceuticals Inc

BioMarin’s pipeline consists of four areas with investigational medicines, which are central nervous system, cardiovascular, musculoskeletal/metabolic, and non-oncology hematology.

BioMarin has positioned itself well as this company’s strategic focus on rare diseases coupled with their solid financial performance makes them highly adaptable to continued growth in the sector. BioMarin’s stock price on May 23, 2025, was $58.01, and has a market cap of 11.5 billion.

FeatureDescription
Therapeutic FocusRare genetic diseases
Key ProductsVOXZOGO®
Revenue Growth15% increase year-over-year in Q1 2025
PipelineCNS, cardiovascular, musculoskeletal/metabolic, hematology therapies
Market CapApprox. $11.5 billion as of 2025

10.Ascentage Pharma

Ascentage Pharma Group International (NASDAQ: AAPG), a China-based biotech company is drawing interests in 2025 due to ich promising oncology pipeline and strategic global expansion. Ascentage raised $126 million in January 2025 through its U.S.

Initial Public Offering (IPO), which was the first biotech IPO of the year . Their leading candidate, olverembatinib (HQP1351), is a third generation BCR-ABL inhibitor undergoing Phase III trials for chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) .

Ascentage Pharma

Also, a BCL-2 inhibitor, lisaftoclax (APG-2575), is in the final stages of testing for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) . These assets have been incorporated into the Chinese Society of Clinical Oncology 2025 guidelines, highlighting their clinical value .

Analysts estimate Ascentage Pharma would be able to turn profitable by 2026 considering the company’s advanced treatments in development and increasing market foothold . As of May 2025, with a share price of $25.12 the company is a strong candidate for investment targeting rapidly growing oncology focused biotech companies .

FeatureDescription
LocationChina-based biotech company
Key CandidatesOlverembatinib (CML, ALL), Lisaftoclax (CLL, SLL)
Recent FundingRaised $126 million in 2025 U.S. IPO
Clinical ImpactIncluded in Chinese Society of Clinical Oncology 2025 guidelines
Growth OutlookExpected profitability by 2026
Visit Now

Conclusion

Summarizing, The Best Biotech Stocks To Buy In 2025 generated considerale attention and is likely to grow further with developing therapies, their respective pipelines, projected stemmed from their finances, and is predicted to strengthen in the future.

Established firms like Moderna, Vertex, and Regeneron combine technology with market-proven products, while emerging firms like Summit and Ascentage show promising breakthroughs. Buying these stocks will help capture the rapidly evolving future of biotechnology.

10 Best Methods To Freeze Your Debit Card Temporarily | Quick & Secure Options
10 Best Methods For Storing Digital Receipts In Bank Apps
10 Best Methods To Freeze Your Debit Card Temporarily – Quick & Safe Options
10 Best Dividend Kings for Decades of Dividend Growth
10 Best Crypto Custody Banks Europe | Secure & Regulated Options
Share This Article
Facebook Email Print
ByFrisco d'Anconia
Follow:
Frisco d'Anconia is a journalist by profession and a Free Market Activist in Africa. He's has been in Bitcoin since 2011 teaching Bitcoin to college students.
Previous Article Bybit’s Shunyet on Bitcoin’s ATH: ‘$125K Is Within Reach’ in Q2 Bybit’s Shunyet on Bitcoin’s ATH: ‘$125K Is Within Reach’ in Q2
Next Article 10 Best Uranium Stocks To Buy – Top Picks for Nuclear Energy Investors 10 Best Uranium Stocks To Buy – Top Picks for Nuclear Energy Investors
10 Best Crypto Marketing Agencies In Kenya For 2025
10 Best Crypto Marketing Agencies In Kenya For 2025
Guide & Crypto Education
BitMine Immersion (BMNR) Announces ETH Holdings Exceeding 2.83 Million Tokens and Total Crypto and Cash Holdings of $13.4 Billion
Press Releases
Bepay money to Launch $1 Million Bitcoin Rewards Program at Invest Web3 Forum Dubai 2025
Bepay money to Launch $1 Million Bitcoin Rewards Program at Invest Web3 Forum Dubai 2025
Press Releases
BC.GAME News Backs Deccan Gladiators as Title Sponsor in 2025 Abu Dhabi T10 League
Press Releases

Latest Published

10 Best Fiat-To-Crypto Gateway Options: for Easy Crypto Payments

10 Best Fiat-To-Crypto Gateway Options: for Easy Crypto Payments

4 months ago
10 Best Merchant Services Providers & Credit Card Processing Companies in USA

10 Best Merchant Services Providers & Credit Card Processing Companies in USA

4 months ago
9 Best Student Loans Without a Co-Signer In 2025 | Top No-Cosigner Options

9 Best Student Loans Without a Co-Signer In 2025 | Top No-Cosigner Options

4 months ago
17 Best High Yield Savings Accounts in Canada (2025) – Compare Top Rates

20 Best High Interest Savings Accounts In Canada (2025)

4 months ago
  • ADVERTISEMENT
  • SUBMIT PR
  • CONTACT
  • GUEST POST
  • ABOUT US
  • DMCA
  • SITEMAP
  • DISCLAIMER
  • PRIVACY POLICY
What Is Solana? A Complete Guide to the Fast and Scalable Blockchain
What Is Solana? A Complete Guide to the Fast and Scalable Blockchain
Trending
10 Best Shoes For Bunions – Comfort, Support & Pain Relief
10 Best Shoes For Bunions – Comfort, Support & Pain Relief
Trending
10 Best Macroeconomics Books-for Students and Professionals
10 Best Macroeconomics Books-for Students and Professionals
Trending
CoinworldstoryCoinworldstory
Follow US
© Coinworldstory News Network. Cws Design Company. All Rights Reserved.
  • ADVERTISEMENT
  • SUBMIT PR
  • CONTACT
  • GUEST POST
  • ABOUT US
  • DMCA
  • SITEMAP
  • DISCLAIMER
  • PRIVACY POLICY
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?